Prescient Therapeutics Appoints New Chief Medical Officer to Drive Cancer Therapy Innovations

Prescient Therapeutics Limited ( (AU:PTX) ) has issued an update.

Prescient Therapeutics Limited has appointed Dr. Marissa Lim as the new Chief Medical Officer, succeeding Dr. Terrence Chew. Dr. Lim, with over 20 years of experience in pharmaceutical and biotech sectors, will lead the clinical development of Prescient’s innovative pipeline, including the Phase 2 study of PTX-100 for Cutaneous T cell lymphoma and the advancement of next-generation cell therapy platforms. This leadership change is expected to bolster Prescient’s efforts in advancing personalized cancer treatments, potentially transforming CAR-T therapies and impacting the lives of cancer patients.

More about Prescient Therapeutics Limited

Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches to cancer, including targeted and cellular therapies. Their lead compound, PTX-100, is a first-in-class inhibitor targeting cancer growth enzymes, with ongoing studies in T cell lymphomas. The company also develops advanced cell therapy platforms like OmniCAR and CellPryme, aimed at enhancing the efficacy of CAR-T therapies.

YTD Price Performance: -6.00%

Average Trading Volume: 478,176

Technical Sentiment Signal: Buy

Current Market Cap: A$37.85M

Learn more about PTX stock on TipRanks’ Stock Analysis page.